About
Novel anti-inflammatory, first-in-class synthetic drugs
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
129
By Phase
PHASE3: 4PHASE1/PHASE2: 1PHASE2: 3
By Status
COMPLETED: 5TERMINATED: 3WITHDRAWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05061771Lead Sponsor
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
PHASE3Withdrawn
Started: May 6, 2022 · Completed: Aug 1, 2022
NCT04784455Lead Sponsor
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
PHASE3Terminated
10 participants
Started: Feb 1, 2021 · Completed: May 15, 2024
NCT04453527Collaborator
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19
N/ACompleted
72 participants
Started: May 28, 2020 · Completed: May 30, 2021
NCT04037891Lead Sponsor
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
PHASE1/PHASE2Terminated
12 participants
Started: Mar 4, 2019 · Completed: Apr 30, 2020
NCT04035733Lead Sponsor
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
PHASE2Completed
9 participants
Started: Sep 25, 2018 · Completed: Apr 29, 2020
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...